Castleview Partners, LLC Biogen Inc. Transaction History

Castleview Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$190.52 - $236.72 $952 - $1,183	5 Added 21.74%	28 $6,000
Q3 2022 Nov 10, 2022	SELL	$194.69 - $268.46 $389 - $536	-2 Reduced 8.0%	23 $6,000
Q2 2022 Aug 17, 2022	SELL	$187.54 - $223.02 $874,874 - $1.04 Million	-4,665 Reduced 99.47%	25 $5,000
Q2 2022 Aug 16, 2022	BUY	$187.54 - $223.02 $875,249 - $1.04 Million	4,667 Added 20291.3%	4,690 $956,000
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $4.09 Million - $5.15 Million	-21,089 Reduced 99.89%	23 $4,000
Q4 2021 Feb 17, 2022	BUY	$223.92 - $287.77 $4.72 Million - $6.07 Million	21,089 Added 91691.3%	21,112 $5.07 Million
Q2 2021 Aug 17, 2021	BUY	$259.0 - $414.71 $5,957 - $9,538	23 New	23 $8,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Castleview Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Castleview Partners, LLC with notifications on news.